Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7Z1CR
|
|||
| Drug Name |
TP-3654
|
|||
| Synonyms |
1361951-15-6; TP3654; UNII-EOB0N7BOY4; EOB0N7BOY4; SGI-9481; 2-((1r,4r)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; SCHEMBL102560; CHEMBL3975308; SCHEMBL19986953; SCHEMBL20794171; SCHEMBL22421478; BDBM242374; BCP30070; EX-A1828; NSC805149; AKOS032960444; CS-6293; NSC-805149; SB17245; TP3654; TP 3654; BS-15262; HY-101126; AK00792306; S6774; US9416132, 8-31; 2-(4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino)cyclohexyl)propan-2-ol; 4-((3-(3-(Trifluoromethyl)phenyl)imidazo(1,2-b)pyridazin-6-yl)amino) -trans-cyclohexyl)propan-2-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Sumitomo Dainippon Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H25F3N4O
|
|||
| Canonical SMILES |
CC(C)(C1CCC(CC1)NC2=NN3C(=NC=C3C4=CC(=CC=C4)C(F)(F)F)C=C2)O
|
|||
| InChI |
1S/C22H25F3N4O/c1-21(2,30)15-6-8-17(9-7-15)27-19-10-11-20-26-13-18(29(20)28-19)14-4-3-5-16(12-14)22(23,24)25/h3-5,10-13,15,17,30H,6-9H2,1-2H3,(H,27,28)
|
|||
| InChIKey |
XRNVABDYQLHODA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1361951-15-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase pim (PIM) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03715504) Study of TP-3654 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.